A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer
Authors
Keywords
PD-1, C-MET, Bispecific antibody, Cancer immunotherapy
Journal
INVESTIGATIONAL NEW DRUGS
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2018-12-04
DOI
10.1007/s10637-018-0689-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics
- (2018) Z. Wu et al. PHARMACOLOGY & THERAPEUTICS
- The making of bispecific antibodies
- (2017) Ulrich Brinkmann et al. mAbs
- Prognostic impact of tumor MET expression among patients with stage IV gastric cancer: a Danish cohort study
- (2016) Rune Erichsen et al. ANNALS OF EPIDEMIOLOGY
- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Immunoglobulin isotype knowledge and application to Fc engineering
- (2016) Randall J Brezski et al. CURRENT OPINION IN IMMUNOLOGY
- PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
- (2016) Weiping Zou et al. Science Translational Medicine
- Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression
- (2015) M Zhu et al. BRITISH JOURNAL OF CANCER
- FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis
- (2015) Rony Dahan et al. CANCER CELL
- CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1
- (2015) Takuya Osada et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection
- (2015) Shohei Eto et al. Gastric Cancer
- Selection strategies for anticancer antibody discovery: searching off the beaten path
- (2015) David Sánchez-Martín et al. TRENDS IN BIOTECHNOLOGY
- Antitumor Efficacy of a Bispecific Antibody That Targets HER2 and Activates T Cells
- (2014) T. T. Junttila et al. CANCER RESEARCH
- Bispecific antibodies rise again
- (2014) Ken Garber NATURE REVIEWS DRUG DISCOVERY
- Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors
- (2014) Elizabeth Smyth et al. OncoTargets and Therapy
- TCR/CD3 activation and co-stimulation combined in one T cell retargeting system improve anti-tumor immunity
- (2014) Marc Cartellieri et al. OncoImmunology
- Targeting T cells to tumor cells using bispecific antibodies
- (2013) Stanley R Frankel et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- The structure of dual-variable-domain immunoglobulin molecules alone and bound to antigen
- (2013) Ivan Correia et al. mAbs
- Structure reveals function of the dual variable domain immunoglobulin (DVD-Ig™) molecule
- (2013) Clarissa G. Jakob et al. mAbs
- MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome
- (2012) H E Lee et al. BRITISH JOURNAL OF CANCER
- Targeting the HGF/Met signaling pathway in cancer therapy
- (2012) Fabiola Cecchi et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Biochemical and pharmacological characterization of human c-Met neutralizing monoclonal antibody CE-355621
- (2012) Neil R. Michaud et al. mAbs
- Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies
- (2012) Christian Klein et al. mAbs
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- (2012) J. M. Taube et al. Science Translational Medicine
- Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab
- (2011) Dirk Nagorsen et al. EXPERIMENTAL CELL RESEARCH
- METAmplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib
- (2011) Jochen K. Lennerz et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib Inhibits the Hepatocyte Growth Factor-Mediated Epithelial Mesenchymal Transition in Hepatocellular Carcinoma
- (2011) T. Nagai et al. MOLECULAR CANCER THERAPEUTICS
- An overview of the c-MET signaling pathway
- (2011) Shawna Leslie Organ et al. Therapeutic Advances in Medical Oncology
- Tumor expression of B7-H4 predicts poor survival of patients suffering from gastric cancer
- (2010) Jingting Jiang et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Monovalency Unleashes the Full Therapeutic Potential of the DN-30 Anti-Met Antibody
- (2010) Giovanni Pacchiana et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Catumaxomab
- (2010) Rolf Linke et al. mAbs
- Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells
- (2010) Y Gan et al. ONCOGENE
- Structural basis for agonism and antagonism of hepatocyte growth factor
- (2010) W. D. Tolbert et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A modular IgG-scFv bispecific antibody topology
- (2009) Kelly Davis Orcutt et al. PROTEIN ENGINEERING DESIGN & SELECTION
- Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody
- (2008) R. Bargou et al. SCIENCE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started